Drug Trial Radar · NCT02045056
Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease
Last checked: Nov 20, 2026Latest source record: Oct 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
May 2014
Primary completion
Jun 30, 2018
Study completion Jun 2019
Sponsor
- Lead sponsor
- Gregory Jicha, 323-5550Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 24, 2014
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 65 years, up to 90 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and efficacy of gemfibrozil in modulating microRNA-107 levels for the prevention of Alzheimer's disease in subjects with intact cognition and mild cognitive impairment
Conditions
- Preclinical Alzheimer's Disease
Interventions
GemfibrozilDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- SafetyTime frame: 52 weeks
- microRNA-107 levelsTime frame: 48 weeks
- beta-amyloid levelsTime frame: 48 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Kentucky
Lexington, Kentucky
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.